SG11202103919RA - Methods of treating cns tumors with tesetaxel - Google Patents
Methods of treating cns tumors with tesetaxelInfo
- Publication number
- SG11202103919RA SG11202103919RA SG11202103919RA SG11202103919RA SG11202103919RA SG 11202103919R A SG11202103919R A SG 11202103919RA SG 11202103919R A SG11202103919R A SG 11202103919RA SG 11202103919R A SG11202103919R A SG 11202103919RA SG 11202103919R A SG11202103919R A SG 11202103919RA
- Authority
- SG
- Singapore
- Prior art keywords
- tesetaxel
- methods
- cns tumors
- treating cns
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862746926P | 2018-10-17 | 2018-10-17 | |
US201962811181P | 2019-02-27 | 2019-02-27 | |
PCT/US2019/049642 WO2020081165A1 (en) | 2018-10-17 | 2019-09-05 | Methods of treating cns tumors with tesetaxel |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202103919RA true SG11202103919RA (en) | 2021-05-28 |
Family
ID=70283506
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202103919RA SG11202103919RA (en) | 2018-10-17 | 2019-09-05 | Methods of treating cns tumors with tesetaxel |
Country Status (12)
Country | Link |
---|---|
US (1) | US20210386720A1 (en) |
EP (1) | EP3866782A4 (en) |
JP (1) | JP2022505222A (en) |
KR (1) | KR20210091713A (en) |
CN (1) | CN113271935A (en) |
AU (1) | AU2019359755A1 (en) |
CA (1) | CA3116853A1 (en) |
IL (1) | IL282389A (en) |
MA (1) | MA53929A (en) |
SG (1) | SG11202103919RA (en) |
TW (1) | TW202027739A (en) |
WO (1) | WO2020081165A1 (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102405044A (en) * | 2009-02-06 | 2012-04-04 | 南加利福尼亚大学 | Therapeutic compositions comprising monoterpenes |
BR112019025164A2 (en) * | 2017-06-02 | 2020-06-16 | Odonate Therapeutics, Inc. | DOSAGE SCHEME FOR TESETAXEL AND CAPECITABINE |
-
2019
- 2019-09-05 JP JP2021521176A patent/JP2022505222A/en active Pending
- 2019-09-05 CN CN201980083400.4A patent/CN113271935A/en active Pending
- 2019-09-05 US US17/286,577 patent/US20210386720A1/en not_active Abandoned
- 2019-09-05 AU AU2019359755A patent/AU2019359755A1/en not_active Abandoned
- 2019-09-05 WO PCT/US2019/049642 patent/WO2020081165A1/en unknown
- 2019-09-05 EP EP19873176.2A patent/EP3866782A4/en not_active Withdrawn
- 2019-09-05 KR KR1020217014765A patent/KR20210091713A/en unknown
- 2019-09-05 SG SG11202103919RA patent/SG11202103919RA/en unknown
- 2019-09-05 CA CA3116853A patent/CA3116853A1/en active Pending
- 2019-09-05 MA MA053929A patent/MA53929A/en unknown
- 2019-09-05 TW TW108132073A patent/TW202027739A/en unknown
-
2021
- 2021-04-18 IL IL282389A patent/IL282389A/en unknown
Also Published As
Publication number | Publication date |
---|---|
MA53929A (en) | 2021-08-25 |
TW202027739A (en) | 2020-08-01 |
JP2022505222A (en) | 2022-01-14 |
US20210386720A1 (en) | 2021-12-16 |
WO2020081165A1 (en) | 2020-04-23 |
AU2019359755A1 (en) | 2021-05-20 |
IL282389A (en) | 2021-06-30 |
EP3866782A1 (en) | 2021-08-25 |
KR20210091713A (en) | 2021-07-22 |
EP3866782A4 (en) | 2022-10-19 |
CN113271935A (en) | 2021-08-17 |
CA3116853A1 (en) | 2020-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL269026A (en) | Methods of treating tumor | |
IL275663A (en) | Methods of treating cancer | |
HK1258098A1 (en) | Methods of treating cancer | |
HK1252272A1 (en) | Methods of treating cancer using anti-ox40 antibodies | |
IL263925A (en) | Methods of treating ovarian cancer | |
IL253462B2 (en) | Treatment of cancer with anti-lap monoclonal antibodies | |
IL260444B (en) | Anti-her2 combinations for treating tumors | |
IL264674B1 (en) | Anti-siglec-7 antibodies for the treatment of cancer | |
IL262342A (en) | Methods of treating cancer | |
SG10202012106WA (en) | Methods for treating inflammatory conditions of the lungs | |
IL286297A (en) | Methods of treating minimal residual cancer | |
ZA201808258B (en) | Methods of treating pancreatic cancer | |
HK1251927A1 (en) | Novel biomarkers and methods of treating cancer | |
SG11202010793UA (en) | Methods of treating cancer | |
IL283337A (en) | Methods of treating whsc1-overexpressing cancers by inhibiting setd2 | |
IL271934A (en) | Methods of treating tumor metastasis | |
EP3894768C0 (en) | Methods of cryo-curing | |
SG11202005163PA (en) | Methods of treating cancer | |
IL281600A (en) | Methods of treating cancer | |
IL280991A (en) | Platelet count-agnostic methods of treating myelofibrosis | |
IL277981A (en) | Methods of treating cancer | |
IL282389A (en) | Methods of treating cns tumors with tesetaxel | |
IL281284A (en) | Methods of treating psoriasis | |
IL269123A (en) | Methods of treating cancer | |
HK1246851A1 (en) | Methods of detecting cancer |